Advancements in Targeted Therapy for Rheumatoid Arthritis
DOI:
https://doi.org/10.61173/cztnnd21Keywords:
Targeted therapy, rheumatoid arthritis, clinical trialsAbstract
In recent years, the treatment of rheumatoid arthritis has broadened the variety. In particular, targeted therapy has become the most concerned treatment. Many of the shortcomings of traditional treatment modalities, such as expensive drugs and severe side effects, can be replaced by targeted therapy. Targeted therapy has not been widely used in clinical treatment, but it has been well understood and studied for many years. At the same time, many kinds of targeted drugs have been studied for the treatment of RA. This article analyzes the direction of several targeted therapy and drug research, about their different use methods, pathways, etc., and some are still under study. There are many research results, successful clinical trials, and significant improvement compared with traditional treatment. It can better treat patients and take care of their physical and mental health. Targeted therapy provides a reference for the subsequent research on the treatment of RA, and is also an excellent improvement of the treatment, but more clinical trials are still needed to truly populalize a variety of targeted therapy to patients.
References
[1] WHO. https://www.who.int/zh/news-room/fact-sheets/detail/ rheumatoid-arthritis.2024.
[2] Wenqing L, Yijun Y, Zunyong L, et al. The Therapeutic Potential of Targeted Nanoparticulate Systems to Treat Rheumatoid Arthritis. Journal of Nanomaterials, 2022, 2022.
[3] Lang L, Shangling Z, Hongyu H, et al. Chemically modified small interfering RNA targeting Hedgehog signaling pathway for rheumatoid arthritis therapy. Molecular Therapy - Nucleic Acids, 2023, 31: 88-104.
[4] Xiu Z, Xin Y, Chenglong W, et al. Targeted co-delivery biomimetic nanoparticles reverse macrophage polarization for enhanced rheumatoid arthritis therapy. Drug Delivery, 2022, 29(1): 1025-1037.
[5] Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells. Seok-Beom Yong, Jee Young Chung, Yoonsung Song, Jaehyun Kim, Sehee Ra, Yong-Hee Kim. Biomaterials, 2019.
[6] Saisai L, XiaoYu He, Tian Yu Wu, Cheng Zhi Tang, Yong Jie Chen, Yan Zhang, Summer, Shi Di Zhao, Chang Hao Xie, Xiao Nan Zhang. Nanoparticle-targeted therapy for rheumatoid arthritis. Journal of Biochemical and Biophysical Chemistry, 2022, 42(07): 1255-1262.
[7] Chen Z, Bozec A, Ramming A, et al. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nat Rev Rheumatol, 2019, 15: 9-17.
[8] Yan C, Wei W. Trp-IDO1,2/TDO2-KynResearch progress of metabolic pathways mediating rheumatoid arthritis. Acta Pharmacologica Sinica, 2019, 54(09): 1547-1553. (in Chinese)
[9] M. Rabiei, S. Kashanian, S. S. Samavati, H. Derakhshankhah, S. Jamasb, and S. J. P. McInnes, “Nanotechnology application in drug delivery to osteoarthritis (OA), rheumatoid arthritis (RA), and osteoporosis (OSP),” Journal of Drug Delivery Science and Technology, vol. 61, article 102011, 2021.
[10] Yoshitomi, H. Regulation of immune responses and chronic inflammation by fibroblast-like synoviocytes. Front. Immunol. 2019,10, 1395.
[11] Nygaard, G., and Firestein, G.S. Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nat. Rev. Rheumatol. 2020, 16,316–333.
[12] Briscoe, J., and Thérond, P.P. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat. Rev. Mol. Cell Biol. 2013, 14, 416–429.
[13] Clara, J.A., Monge, C., Yang, Y., and Takebe, N. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. Nat. Rev. Clin. Oncol. 2020, 17, 204–232.
[14] Su, Y., Xing, H., Kang, J., Bai, L., and Zhang, L. Role of the Hedgehog signaling pathway in rheumatic diseases: an overview. Front. Immunol. 2022, 13, 940455.
[15] Sekulic, A., Migden, M.R., Oro, A.E., et al. Efficacy and Dean&Francis safety of vismodegib in advanced basal-cell carcinoma. N. Engl. J. Med. 2012, 366, 2171–2179.
[16] Setten, R.L., Rossi, J.J., and Han, S.P. The current state and future directions of RNAi-based therapeutics. Nat. Rev. Drug Discov. 2019, 18, 421–446.
[17] Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., and Liang, X.J.Therapeutic siRNA: state of the art. Signal Transduct. Target. Ther. 2020, 5, 101.
[18] Roberts, T.C., Langer, R., and Wood, M.J.A. Advances in oligonucleotide drug delivery. Nat. Rev. Drug Discov. 2020, 19, 673–694.
[19] Neklesa, T. K., Winkler, J. D. & Crews, C. M. Targeted protein degradation by PROTACs. Pharmacol Ther. 2017, 174, 138-144.
[20] Saraswat, A. L. et al. Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs). Drug Discov Today. 2022, 28, 103387.
[21] Kargbo, R. B. PROTAC-Mediated Degradation of Janus Kinase as a Therapeutic Strategy for Cancer and Rheumatoid Arthritis. ACS Med Chem Lett. 2022, 12, 945-946.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
